Remdesivir lowered risk of death among hospitalized COVID patients by 54% --study

Remdesivir tied to 54% lower risk of death among hospitalized COVID patients A comparison study based on two large, open-label studies links the antiviral drug remdesivir (Veklury) to a 54% lower risk of all-cause death and shorter hospital stays compared with standard of care (SOC) alone in hospitalized COVID-19 patients requiring supplemental oxygen in 2020.  CIDRAP

...

In the United States, remdesivir is recommended for hospitalized COVID-19 patients and those with mild or moderate illness at high risk of severe disease within 7 days of symptom onset.